Eli Kedar

3.1k total citations
117 papers, 2.5k citations indexed

About

Eli Kedar is a scholar working on Immunology, Oncology and Molecular Biology. According to data from OpenAlex, Eli Kedar has authored 117 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 77 papers in Immunology, 29 papers in Oncology and 25 papers in Molecular Biology. Recurrent topics in Eli Kedar's work include Immunotherapy and Immune Responses (51 papers), Immune Cell Function and Interaction (43 papers) and Monoclonal and Polyclonal Antibodies Research (21 papers). Eli Kedar is often cited by papers focused on Immunotherapy and Immune Responses (51 papers), Immune Cell Function and Interaction (43 papers) and Monoclonal and Polyclonal Antibodies Research (21 papers). Eli Kedar collaborates with scholars based in Israel, United States and Netherlands. Eli Kedar's co-authors include Benjamin Bonavida, Yechezkel Barenholz, Manuel O. Landázuri, Ilan Babai, Sarit Samira, John L. Fahey, Aviva Joseph, David Weiss, Barbara Ikejiri and Noam Emanuel and has published in prestigious journals such as Nature, Journal of Biological Chemistry and The Journal of Experimental Medicine.

In The Last Decade

Eli Kedar

115 papers receiving 2.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Eli Kedar Israel 30 1.6k 715 456 403 312 117 2.5k
Timothy Kuo United States 14 1.8k 1.1× 741 1.0× 484 1.1× 316 0.8× 536 1.7× 19 3.0k
Giuseppe Scala Italy 30 1.4k 0.9× 988 1.4× 565 1.2× 338 0.8× 278 0.9× 73 2.9k
Walid Mourad Canada 33 1.9k 1.2× 775 1.1× 267 0.6× 272 0.7× 420 1.3× 120 3.3k
Ramila Philip United States 28 1.5k 0.9× 1.3k 1.8× 580 1.3× 423 1.0× 284 0.9× 81 3.0k
Anders Elm Pedersen Denmark 31 1.4k 0.9× 914 1.3× 618 1.4× 200 0.5× 214 0.7× 87 2.4k
Erwin Rüde Germany 28 2.4k 1.5× 701 1.0× 464 1.0× 379 0.9× 370 1.2× 88 3.6k
Hilary S. Warren Australia 24 1.9k 1.2× 506 0.7× 380 0.8× 203 0.5× 140 0.4× 66 2.7k
S H Herrmann United States 29 2.1k 1.3× 669 0.9× 759 1.7× 233 0.6× 461 1.5× 59 3.0k
Takushi Tadakuma Japan 26 815 0.5× 828 1.2× 261 0.6× 145 0.4× 186 0.6× 86 2.0k
Anne M. VanBuskirk United States 27 1.2k 0.7× 611 0.9× 346 0.8× 259 0.6× 150 0.5× 51 2.3k

Countries citing papers authored by Eli Kedar

Since Specialization
Citations

This map shows the geographic impact of Eli Kedar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eli Kedar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eli Kedar more than expected).

Fields of papers citing papers by Eli Kedar

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eli Kedar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eli Kedar. The network helps show where Eli Kedar may publish in the future.

Co-authorship network of co-authors of Eli Kedar

This figure shows the co-authorship network connecting the top 25 collaborators of Eli Kedar. A scholar is included among the top collaborators of Eli Kedar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eli Kedar. Eli Kedar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Cowman, Mary K., Jin Ryoun Kim, Haim Ovadia, et al.. (2021). MTADV 5-MER peptide suppresses chronic inflammations as well as autoimmune pathologies and unveils a new potential target-Serum Amyloid A. Journal of Autoimmunity. 124. 102713–102713. 14 indexed citations
2.
Mitchell, Leslie A., Aviva Joseph, Eli Kedar, Yechezkel Barenholz, & E. Galun. (2006). Mucosal immunization against hepatitis A: Antibody responses are enhanced by co-administration of synthetic oligodeoxynucleotides and a novel cationic lipid. Vaccine. 24(25). 5300–5310. 19 indexed citations
3.
Joseph, Aviva, Sarit Samira, Hagit Eliyahu, et al.. (2005). A new intranasal influenza vaccine based on a novel polycationic lipid—ceramide carbamoyl-spermine (CCS). Vaccine. 24(18). 3990–4006. 81 indexed citations
4.
Achdout, Hagit, Tal I. Arnon, Gal Markel, et al.. (2003). Enhanced Recognition of Human NK Receptors After Influenza Virus Infection. The Journal of Immunology. 171(2). 915–923. 63 indexed citations
5.
Ben‐Yehuda, Arie, Aviva Joseph, Evelyne Zeira, et al.. (2003). Immunogenicity and safety of a novel liposomal influenza subunit vaccine (INFLUSOME‐VAC) in young adults. Journal of Medical Virology. 69(4). 560–567. 32 indexed citations
6.
Boerman, Otto C., et al.. (2001). Liposomes as sustained release system for human interferon-γ: biopharmaceutical aspects. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids. 1530(2-3). 134–145. 60 indexed citations
7.
8.
Bishara, Amal, et al.. (1998). Cytokine production in human mixed leukocyte reactions performed in serum-free media. Journal of Immunological Methods. 215(1-2). 187–190. 5 indexed citations
9.
Emanuel, Noam, Eli Kedar, Elijah M. Bolotin, Nechama I. Smorodinsky, & Yechezkel Barenholz. (1996). Targeted Delivery of Doxorubicin via Sterically Stabilized Immunoliposomes: Pharmacokinetics and Biodistribution in Tumor-bearing Mice. Pharmaceutical Research. 13(6). 861–868. 50 indexed citations
10.
Emanuel, Noam, Eli Kedar, Elijah M. Bolotin, Nechama I. Smorodinsky, & Yechezkel Barenholz. (1996). Preparation and Characterization of Doxorubicin-Loaded Sterically Stabilized Immunoliposomes. Pharmaceutical Research. 13(3). 352–359. 32 indexed citations
11.
Gazit, Zulma & Eli Kedar. (1994). Chemotherapy-induced modulation of natural killer and lymphokine-activated killer cell activity in euthymic and athymic mice. Cancer Immunology Immunotherapy. 38(4). 243–252. 18 indexed citations
12.
Kedar, Eli, et al.. (1994). Delivery of Cytokines by Liposomes. II. Interleukin-2 Encapsulated in Long-Circulating Sterically Stabilized Liposomes. Journal of Immunotherapy. 16(2). 115–124. 31 indexed citations
13.
14.
Bishara, Amal, Eli Kedar, B. Leshem, et al.. (1993). A 2‐DAY MLR PROCEDURE FOR MARROW DONOR SELECTION FOR ALLOGENEIC BONE MARROW TRANSPLANTATION. International Journal of Immunogenetics. 20(4). 289–292. 1 indexed citations
15.
Leshem, B. & Eli Kedar. (1990). Cytotoxic T lymphocytes reactive against a syngeneic murine tumor and their specific suppressor T cells are both elicited by in vitro allosensitization.. The Journal of Experimental Medicine. 171(4). 1057–1071. 6 indexed citations
16.
Kedar, Eli, et al.. (1989). Chemo-immunotherapy of murine tumors using interleukin-2 (IL-2) and cyclophosphamide. Cancer Immunology Immunotherapy. 29(1). 74–8. 31 indexed citations
17.
18.
Slavin, S & Eli Kedar. (1988). Current problems and future goals in clinical bone marrow transplantation. Blood Reviews. 2(4). 259–269. 7 indexed citations
19.
20.
Kedar, Eli & Benjamin Bonavida. (1975). Studies on the induction and expression of T cell-mediated immunity. IV. Non-overlapping populations of alloimmune cytotoxic lymphocytes with specificity for tumor-associated antigens and transplantation antigens.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 115(5). 1301–8. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Timothy Kuo Breakdown of academic impact, for papers by Giuseppe Scala Breakdown of academic impact, for papers by Walid Mourad Breakdown of academic impact, for papers by Ramila Philip Breakdown of academic impact, for papers by Anders Elm Pedersen Breakdown of academic impact, for papers by Erwin Rüde Breakdown of academic impact, for papers by Hilary S. Warren Breakdown of academic impact, for papers by S H Herrmann Breakdown of academic impact, for papers by Takushi Tadakuma Breakdown of academic impact, for papers by Anne M. VanBuskirk
Rankless by CCL
2026